
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Must reads about the latest news and trends in healthcare careers. . .
This roundup highlights healthcare career-related articles culled from across the Web to help you learn what's next.
This article was first published on






